Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7198MR)

This product GTTS-WQ7198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7198MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6268MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ7937MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ10884MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ12100MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ6561MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ10801MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ14815MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ10026MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW